
Phatsawee Jansook

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1012201/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Effect of salt formation on γ-cyclodextrin solubilization of irbesartan and candesartan and the chemical stability of their ternary complexes. Journal of Drug Delivery Science and Technology, 2022, 67, 102980.	1.4	4
2	Angiotensin converting enzyme inhibitors/cyclodextrin inclusion complexes: solution and solid-state characterizations and their thermal stability. Journal of Inclusion Phenomena and Macrocyclic Chemistry, 2022, 102, 347-358.	0.9	2
3	Cyclodextrin-based Pickering nanoemulsions containing amphotericin B: Part I. evaluation of oil/cyclodextrin and amphotericin B/cyclodextrin inclusion complexes. Journal of Drug Delivery Science and Technology, 2022, 68, 103118.	1.4	3
4	Cyclodextrin-based Pickering nanoemulsions containing amphotericin B: Part II. Formulation, antifungal activity, and chemical stability. Journal of Drug Delivery Science and Technology, 2022, 69, 103174.	1.4	6
5	Self-assembled γ-cyclodextrin as nanocarriers for enhanced ocular drug bioavailability. International Journal of Pharmaceutics, 2022, 618, 121654.	2.6	18
6	Effect of Soluplus [®] on γ-cyclodextrin solubilization of irbesartan and candesartan and their nanoaggregates formation. Pharmaceutical Development and Technology, 2022, 27, 9-18.	1.1	0
7	Physicochemical and Stability Evaluation of Topical Niosomal Encapsulating Fosinopril/Î ³ -Cyclodextrin Complex for Ocular Delivery. Pharmaceutics, 2022, 14, 1147.	2.0	14
8	Angiotensin Receptor Blockers in cyclodextrin nanoparticle eye drops: Ocular pharmacokinetics and pharmacologic effect on intraocular pressure. Acta Ophthalmologica, 2021, 99, 376-382.	0.6	13
9	Solubility and stability of cediranib maleate. Journal of Drug Delivery Science and Technology, 2021, 62, 102359.	1.4	2
10	Bio-Distribution and Pharmacokinetics of Topically Administered Î ³ -Cyclodextrin Based Eye Drops in Rabbits. Pharmaceuticals, 2021, 14, 480.	1.7	8
11	Cyclodextrin-based formulation of carbonic anhydrase inhibitors for ocular delivery – A review. International Journal of Pharmaceutics, 2021, 606, 120955.	2.6	12
12	Aqueous solubility of kinase inhibitors: I the effect of hydrophilic polymers on their Î ³ -cyclodextrin solubilization. Journal of Drug Delivery Science and Technology, 2020, 55, 101462.	1.4	12
13	Aqueous solubility of kinase inhibitors: II the effect of hexadimethrine bromide on the dovitinib/l̃³-cyclodextrin complexation. Journal of Drug Delivery Science and Technology, 2020, 55, 101463.	1.4	6
14	Antifungal activity of econazole nitrate/cyclodextrin complex: Effect of pH and formation of complex aggregates. International Journal of Pharmaceutics, 2020, 574, 118896.	2.6	10
15	The investigation of binary and ternary sulfobutylether-β-cyclodextrin inclusion complexes with asiaticoside in solution and in solid state. Carbohydrate Research, 2020, 498, 108190.	1.1	27
16	Effect of porcine pancreatic α-amylase on dexamethasone release from aqueous solution containing natural γ-cyclodextrin. International Journal of Pharmaceutics, 2020, 585, 119452.	2.6	5
17	Development of amphotericin B nanosuspensions for fungal keratitis therapy: effect of self-assembled γ-cyclodextrin. Journal of Pharmaceutical Investigation, 2020, 50, 513-525.	2.7	17
18	Development of in situ gel containing asiaticoside/cyclodextrin complexes. Evaluation in culture human periodontal ligament cells (HPLDCs). International Journal of Pharmaceutics, 2020, 586, 119589.	2.6	17

Phatsawee Jansook

#	Article	IF	CITATIONS
19	Solubilization and in vitro permeation of dovitinib/cyclodextrin complexes and their aggregates. Journal of Inclusion Phenomena and Macrocyclic Chemistry, 2020, 97, 195-203.	0.9	8
20	Aqueous solubility of kinase inhibitors: III the effect of acidic counter ion on the dovitinib/γ-cyclodextrin complexation. Journal of Inclusion Phenomena and Macrocyclic Chemistry, 2020, 98, 57-67.	0.9	3
21	Self-assembly of cyclodextrin complexes: detection, obstacles and benefits. Die Pharmazie, 2020, 75, 307-312.	0.3	8
22	Development of celecoxib eye drop solution and microsuspension: A comparative investigation of binary and ternary cyclodextrin complexes. Carbohydrate Polymers, 2019, 225, 115209.	5.1	25
23	Amphotericin B loaded solid lipid nanoparticles (SLNs) and nanostructured lipid carrier (NLCs): physicochemical and solid-solution state characterizations. Drug Development and Industrial Pharmacy, 2019, 45, 560-567.	0.9	40
24	Topical drug delivery to the posterior segment of the eye: Dexamethasone concentrations in various eye tissues after topical administration for up to 15 days to rabbits. Journal of Drug Delivery Science and Technology, 2018, 45, 449-454.	1.4	34
25	Cyclodextrin solubilization of celecoxib: solid and solution state characterization. Journal of Inclusion Phenomena and Macrocyclic Chemistry, 2018, 90, 75-88.	0.9	17
26	Cyclodextrins: structure, physicochemical properties and pharmaceutical applications. International Journal of Pharmaceutics, 2018, 535, 272-284.	2.6	518
27	Topical drug delivery to the posterior segment of the eye: The effect of benzalkonium chloride on topical dexamethasone penetration into the eye in vivo. Journal of Drug Delivery Science and Technology, 2018, 48, 125-127.	1.4	11
28	Amphotericin B-loaded solid lipid nanoparticles (SLNs) and nanostructured lipid carrier (NLCs): effect of drug loading and biopharmaceutical characterizations. Drug Development and Industrial Pharmacy, 2018, 44, 1693-1700.	0.9	35
29	Solubility of Cyclodextrins and Drug/Cyclodextrin Complexes. Molecules, 2018, 23, 1161.	1.7	407
30	Evaluation of Î ³ -cyclodextrin effect on permeation of lipophilic drugs: application of cellophane/fused octanol membrane. Pharmaceutical Development and Technology, 2017, 22, 562-570.	1.1	14
31	Pharmacokinetics of a new, nasal formulation of naloxone. European Journal of Clinical Pharmacology, 2017, 73, 555-562.	0.8	31
32	Cyclodextrin-based telmisartan ophthalmic suspension: Formulation development for water-insoluble drugs. International Journal of Pharmaceutics, 2016, 507, 21-31.	2.6	26
33	Cyclodextrin–poloxamer aggregates as nanocarriers in eye drop formulations: dexamethasone and amphotericin B. Drug Development and Industrial Pharmacy, 2016, 42, 1446-1454.	0.9	34
34	Development of a cyclodextrin-based aqueous cyclosporin A eye drop formulations. International Journal of Pharmaceutics, 2015, 493, 86-95.	2.6	39
35	Formation and stability assessment of self-assembled nanoparticles from large Mw chitosan and sulfobutylether-β-cyclodextrin. Journal of Drug Delivery Science and Technology, 2015, 30, 478-485.	1.4	11
36	Development of eye drops containing antihypertensive drugs: formulation of aqueous irbesartan/γCD eye drops. Pharmaceutical Development and Technology, 2015, 20, 626-632.	1.1	25

Phatsawee Jansook

#	Article	IF	CITATIONS
37	Î ³ -Cyclodextrin Nanoparticle Eye Drops with Dorzolamide: Effect on Intraocular Pressure in Man. Journal of Ocular Pharmacology and Therapeutics, 2014, 30, 35-41.	0.6	24
38	Surface activity and self-aggregation ability of three cationic quaternized aminocalix[4]arenes. Journal of Inclusion Phenomena and Macrocyclic Chemistry, 2014, 79, 473-483.	0.9	3
39	Effect of γ-cyclodextrin on solubilization and complexation of irbesartan: Influence of pH and excipients. International Journal of Pharmaceutics, 2014, 474, 80-90.	2.6	29
40	Topical drug delivery to the eye: dorzolamide. Acta Ophthalmologica, 2012, 90, 603-608.	0.6	61
41	Drug loading in cyclodextrin polymers: dexamethasone model drug. Journal of Inclusion Phenomena and Macrocyclic Chemistry, 2011, 69, 377-382.	1.6	17
42	Self-assembly of cyclodextrin complexes: Aggregation of hydrocortisone/cyclodextrin complexes. International Journal of Pharmaceutics, 2011, 407, 174-183.	2.6	63
43	Topical Dexamethasone-Cyclodextrin Microparticle Eye Drops for Diabetic Macular Edema. , 2011, 52, 7944.		90
44	Effect of self-aggregation of \hat{I}^3 -cyclodextrin on drug solubilization. Journal of Inclusion Phenomena and Macrocyclic Chemistry, 2010, 68, 229-236.	1.6	46
45	Cyclodextrins as solubilizers: Formation of complex aggregates. Journal of Pharmaceutical Sciences, 2010, 99, 719-729.	1.6	107
46	Self-assembled cyclodextrin aggregates and nanoparticles. International Journal of Pharmaceutics, 2010, 387, 199-208.	2.6	274
47	yCD/HPyCD Mixtures as Solubilizer: Solid-State Characterization and Sample Dexamethasone Eye Drop Suspension. Journal of Pharmacy and Pharmaceutical Sciences, 2010, 13, 336.	0.9	38
48	Cyclodextrin solubilization of carbonic anhydrase inhibitor drugs: Formulation of dorzolamide eye drop microparticle suspension. European Journal of Pharmaceutics and Biopharmaceutics, 2010, 76, 208-214.	2.0	65
49	CDs as solubilizers: Effects of excipients and competing drugs. International Journal of Pharmaceutics, 2009, 379, 32-40.	2.6	77
50	Î ³ CD/HPÎ ³ CD: Synergistic solubilization. International Journal of Pharmaceutics, 2008, 363, 217-219.	2.6	25
51	Carvedilol: Solubilization and Cyclodextrin Complexation: A Technical Note. AAPS PharmSciTech, 2008, 9, 425-430.	1.5	82